Xencor (XNCR) Competitors

Xencor (NASDAQ:XNCR) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.

Do institutionals & insiders hold more shares of XNCR or LYEL?

66.1% of Lyell Immunopharma shares are owned by institutional investors. 4.8% of Xencor shares are owned by company insiders. Comparatively, 25.1% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has higher earnings and valuation, XNCR or LYEL?

Xencor has higher revenue and earnings than Lyell Immunopharma. Xencor is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$127.23M	5.33	-$126.09M	-$3.06	-3.11
Lyell Immunopharma	$65K	2,143.74	-$234.63M	-$25.00	-0.38

Does the MarketBeat Community believe in XNCR or LYEL?

Xencor received 495 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 73.13% of users gave Xencor an outperform vote while only 43.75% of users gave Lyell Immunopharma an outperform vote.

Company	Underperform	Outperform
Xencor	Outperform Votes 509 73.13%	Underperform Votes 187 26.87%
Lyell Immunopharma	Outperform Votes 14 43.75%	Underperform Votes 18 56.25%

Does the media prefer XNCR or LYEL?

In the previous week, Lyell Immunopharma had 1 more articles in the media than Xencor. MarketBeat recorded 7 mentions for Lyell Immunopharma and 6 mentions for Xencor. Xencor's average media sentiment score of 1.07 beat Lyell Immunopharma's score of 0.66 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is XNCR or LYEL more profitable?

Xencor has a net margin of -232.77% compared to Lyell Immunopharma's net margin of -323,792.09%. Xencor's return on equity of -30.92% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-232.77%	-30.92%	-21.74%
Lyell Immunopharma	-323,792.09%	-34.64%	-30.02%

Do analysts recommend XNCR or LYEL?

Xencor currently has a consensus target price of $29.50, indicating a potential upside of 209.87%. Lyell Immunopharma has a consensus target price of $20.00, indicating a potential upside of 112.54%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Which has more risk & volatility, XNCR or LYEL?

Xencor has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500.

Summary

Xencor beats Lyell Immunopharma on 15 of the 19 factors compared between the two stocks.